10x Insights
Loading account…
FACDX

Fidelity Advisor Health Care Fund

Actively managedEquityOpen-end fund
Fidelity Advisor Series VII: FACDX · FHCCX · FACTX · FHCIX · FIKCXHoldings as of Apr 30, 2026Filed Jun 26, 2026

Actively managed U.S. stock fund

As of its 2026 Q2 report, Fidelity Advisor Health Care Fund held 138 positions with $2.89B in net assets. Its ten largest holdings made up 38.4% of the fund. The FACDX share class costs 0.93% a year. Over the 12 months to May 2026, FACDX returned 19.4%, with dividends reinvested. In 2026 Q3 it added 43 new positions and exited 27.

2026 Q2 holdings and allocationChanges are against the previous quarter, 2026 Q2Headline fees and returns use the FACDX share class
Expense ratio · FACDX
0.93%
$93 a year for every $10,000 invested
0.56% – 1.68% across the 5 classes
$2.89B
The whole fund, all share classes
138 holdings
38.4%in the top 10
Weight held in the ten largest holdings
Top 25 hold 59.4%
Return, 1 year · FACDX
+19.4%
With dividends, to May 2026
3 yr total +20.4% · 5 yr total +11.2%
What this fund is
Objective, as filed

Fidelity Advisor Health Care Fund seeks capital appreciation.

Strategy, summarised

The fund invests primarily in common stocks of companies principally engaged in health care and medicine, including biotechnology, pharmaceuticals, medical devices and equipment, and health care facilities and managed plans, using fundamental analysis of financial condition, industry position, and market conditions to select holdings. The fund normally maintains at least 80% of assets in health care securities and may invest in both domestic and foreign issuers. As of December 11, 2025, the fund's 80% policy includes derivative instruments providing exposure to health care investments or related market risk factors.

What you own

per cent of the fund
CompanyWeightValue
6.93%
$200.00M
6.79%
$195.95M
5.67%
$163.65M
3.62%
$104.41M
3.02%
$87.06M
2.79%
$80.65M
ASCENDIS PHARMA A/S
2.70%
$77.99M
2.44%
$70.56M
2.27%
$65.42M
2.23%
$64.24M
Showing 1–10 of 138 · the top 10 are 38.45% of the fund, the top 25 are 59.42%

Reported price is the fund's own reported value divided by its own reported shares at 2026-04-30 — not a live quote, and not what the fund paid.

All 138 holdings, with the share counts as filed, open with a free account.

What the fund is made of

Percentages are of fund net assets. Rounding, liabilities and short positions can make totals differ from 100%.

101.41%
of net assets
Stocks99.72%
Cash & short-term1.51%
Bonds0.18%

By sector

Health Care
84.6%
International
10.2%
Cash
2.7%
Other
2.4%
1 other sector
0.1%

How it has done

Total return, dividends reinvested · to May 2026

FACDX share class · total returns with dividends reinvested

1 year
+19.36%
3 years
+20.41%
Cumulative, not per year
5 years
+11.17%
Cumulative, not per year
Largest decline in 3 years
-13.76%
From a previous high to a later low
Cumulative return, last three years· Aug 2023 – May 2026

Volatility over the last 12 months: 13.42%. Past returns are a record, not a forecast.

Jun 2026 and Jul 2026 have been filed since the trailing figures were struck, so they are not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.

The 5 share classes hold the same portfolio

Share classExpense ratio1 year3 years5 yearsWorst fall
0.93%+19.36%+20.41%+11.17%-13.76%
1.68%+18.47%+18.37%+8.21%-13.97%
1.18%+19.06%+19.49%+9.83%-13.88%
0.68%+19.66%+21.32%+12.62%-13.59%
0.56%+19.81%+21.75%+13.33%-13.54%

These classes hold the same portfolio, so the 5.11pp spread over 5 years is the cost difference between them — roughly 1.02pp a year — not a difference in what they own.

Fees & fund details

Fidelity Advisor Health Care Fund is an actively managed U.S. equity fund.

Asset class
Equity
Region
United States
Management
Actively managed
Fund type
Open-end fund
Expense ratio, by class
0.56% – 1.68%· FACDX 0.93%
Portfolio turnover
52.00% a year · as of 2025 Q3

Turnover is how much of the portfolio was replaced in a year.

Classified from what the fund holds, not from its name · 2026 Q2. The summary is a paraphrase of the prospectus; the objective is verbatim.

What changed this quarter

2026 Q3 vs 2026 Q2

Positions that entered or left the fund since its previous filing. Positions that were only resized are not listed.

43 new· the largest 8

SARTORIUS STEDIM BIOTECH
PARABILIS MEDICINES INC
FIRST TRACKS BIOTHERAPEUTICS INCTRAX
DAMORA THERAPEUTICS INC

27 exited· the largest 8

NUVALENT INCNUVL
ROCHE HOLDING AG
CRINETICS PHARMACEUTICALS INCCRNX

Debt profile

What this fund holds — value-weighted across its bond and securitized long positions · as of 2026-04-30

Avg coupon
0.07%
Avg maturity
0.71 yr
Coupon type

Share of the fund's debt by how its coupon behaves — the fact that decides whether a rate move reaches this portfolio at all.

29%
floating
Fixed rate71.2%
Floating rate28.8%
Maturity ladder

Share of the fund's debt value in each maturity band, shortest first.

<1y10y+
<1y71.2%
10y+28.8%
Flagged holdings
Defaulted: none reported
In arrears: none reported
Paid in kind: none reported

Based on what filers reported; a filer that never reported a flag also reads as none.

Connected research

Understand how this fund fits with the rest.

Explore shared holdings, compare funds and follow their businesses with your connected AI:

  • “Where do my funds overlap — FACDX, QQQ and the fund in my 401(k)?”
  • “How do this fund’s ten biggest holdings stack up against each other?”
  • “For my target-date fund, what’s the real stock-and-bond mix once you look through it?”
See how it works →All research tools with a subscription. Use your own AI account.